Lupin expects sales to grow by around 25% in next 3 yrs

Commenting on the US market, it said it is looking to sustain growth levels of up to 25% in the current fiscal

Press Trust of India New Delhi
Last Updated : Apr 21 2013 | 1:12 PM IST
Drug maker Lupin expects its sales to continue growing at around 25% globally for the next three years with contributions coming from all the markets where it is present.

"If the past is prescriptive of the future, then we should continue to grow at the current growth levels -- clock in a minimum growth of 22-25% on all counts globally for the next three years," Lupin President (Finance & Planning) and CFO S Ramesh told PTI.

When asked which markets would drive the growth, he said: "The good thing about Lupin is that in fact, our growth has been secular. It has not been restricted to America or India, it has been across various markets."

The Mumbai-based firm which is yet to announce its financial results for the 2012-13 fiscal had posted net sales of Rs 6,959.7 crore for the 2011-12 fiscal.

Commenting on the US market, Ramesh said Lupin is looking to sustain growth levels of up to 25% in the current fiscal.

"We believe that going forward, one could look at us sustaining growth levels in the US at the current levels, a minimum growth of 23 to 25% at the current levels for FY 2014," he added.

The company had posted net sales of Rs 2,530.3 crore for the 2011-12 fiscal in the US market.

The company, which already has 11 approvals in the oral contraceptive space in the US, recently received a favourable ruling form a US court paving the way for it to introduce a generic version of Bayer AG's Yaz tablets in American market.

Commenting on the India business, Ramesh it is likely to grow by 20% in the next three years.

"Our growth rate for the next two to three years should be between 18-20%. So, it is business as usual in India," he added.

He added that the company would continue to add new therapies to its portfolio, bolster it with new drugs, in-licensing agreements and strategic alliances with like minded peers without specifying details.

Lupin's India region sales stood at Rs 1,905.9 crore in 2011-12.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 21 2013 | 1:03 PM IST

Next Story